Persephone Biosciences is a biotechnology company leveraging artificial intelligence to evaluate and decode the metabolic relationships between the gut microbiome and the immune system. Persephone’s technology platform collects and analyzes gut microbiota samples. The company then uses machine learning and systems biology tools to study the impact of gut microbes on patient prognosis with the goal of developing microbial cell immunotherapies to be taken in conjunction with many of the market-leading drugs from Merck, Bristol-Myers Squibb, and AstraZeneca. Not only does Persephone Biosciences believe its technology has the opportunity to help improve the efficacy for these checkpoint inhibitor drugs for cancer, but also that it may be applicable to other diseases, like COVID-19.
